Abstract
Stress-activated signaling cascades are affected by altered redox potential. Key contributors to altered redox potential are reactive oxygen species (ROS) which are formed, in most cases, by exogenous genotoxic agents including irradiation, inflammatory cytokines and chemical carcinogens. ROS and altered redox potential can be considered as the primary intracellular changes which regulate protein kinases, thereby serving as an important cellular component linking external stimuli with signal transduction in stress response. The mechanisms, which underlie the ROS-mediated response, involve direct alteration of kinases and transcription factors, and indirect modulation of cysteine-rich redox-sensitive proteins exemplified by thioredoxin and glutathione S-transferase. This review summarizes the current understanding of the mechanisms contributing to ROS-related changes in key stress activated signaling cascades.
Introduction
Homeostatic control of reactive oxygen species (ROS) is one of the key determinants in maintaining cell growth pathways which can incorporate proliferation (Biguet et al., 1994) apoptosis (reviewed by McConkey and Orrenius, 1996; Wang et al., 1998a; Tan et al., 1998) and senescence (reviewed in Powis et al., 1995). ROS include superoxide, singlet O2, H2O2, and the highly reactive hydroxyl radical. Intercellular levels of ROS are influenced by a number of endogenous and exogenous processes, and controlled by several radical scavenging enzymes. Variability or inductive changes in the expression of these enzymes can significantly influence cellular redox potential. Such changes have been shown to occur during differentiation, aging and senescence (Chen et al., 1995). Exogenous agents which induce ROS formation include chemical and physical carcinogens and various cytokines. Common to all, is their ability to produce directly or indirectly electrophilic metabolites capable of generating reactive oxygen (reviewed by Primiano et al., 1997). Such ROS can alter signal transduction cascades (reviewed by Chakraborti and Chakraborti, 1998) as well as induce changes in transcription factors that mediate immediate cellular stress responses (reviewed by Sen and Packer, 1996; Monterio and Stern, 1996; Lander et al., 1996; Piette et al., 1997). Almost every gene that has been implicated in response to stress has also been shown to be affected by altered redox or ROS levels. Table 1 lists the kinases and respective transcription factor substrates that have been found to be ROS-responsive. The data provided in Table 1 represent a fraction of the abundant information accumulated which suggest that ROS-mediated changes are found in different tissue types and cell systems, illustrating the preponderance of ROS effects.
While the mechanisms underlying ROS induced alterations of kinase and transcription factor activities are not completely understood, progress over the past couple of years may provide new insight into the regulation of stress responsive proteins by ROS. The nature of ROS elicited cellular changes can be divided into two major categories: (i) the direct effect of ROS on the kinase or transcription factor, which can alter conformation and activity. (ii) the effect of cysteine rich, redox-sensitive proteins, which have been shown to play important roles in the regulation of stress responsive proteins. Oxidative conditions produce conformational changes and generation of dimers/multimers of these redox responsive proteins. In most cases, their association with, and regulatory effect on respective signaling molecules is neutralized. These redox responsive proteins include thioredoxin (reviewed by Russel, 1995) and glutathione S-transferase (GST; Tew 1994; Hayes and Pulford, 1995). This review summarizes the current knowledge of ROS effects on stress responsive proteins and highlights present understanding of possible underlying mechanisms.
ROS-induced modification of redox sensitive proteins which regulate stress kinases
Cysteine-rich molecules have been implicated in the response to altered redox potential and generation of ROS. In all cases, ROS causes the formation of intra- or inter-molecular disulfide bond between respective cysteines. Disulfide bridges within the molecule (intra-) alter protein conformation; disulfide bonds between cysteine rich molecules (inter-) create dimers and multimers potentially influencing association with other cellular proteins. Such changes have been shown to occur in redox-sensitive proteins such as thioredoxin and GST. In most cases the formation of dimers results in the dissociation of the redox sensitive molecule from its associated protein. There appears to be a reasonably linear relationship between the degree of oxidative stress, the formation of disulfide species and the induction of stress responsive proteins. Thioredoxin has been the best characterized cysteine-rich redox-responsive protein implicated in the regulation of several stress responsive proteins via direct or intermediate interactions (reviewed in Schulze-Osthoff et al., 1995; Sen and Packer, 1996; Flohe et al., 1997; Piette et al., 1997). The recent identification of thioredoxin as an inhibitor of stress kinase ASK1 (Saitoh et al., 1998), has shed new light on the modes of redox regulatable stress response. Similarly, the identification of GSTP1-1 as an inhibitor of JNK signaling (Adler et al., 1999) creates an additional paradigm for the regulation of stress kinases. In both cases, the inhibition of the stress kinases is mediated via the association with the respective redox sensitive molecule, which takes place under non-stressed growth conditions.
Thioredoxin-ASK1
Screening for ASK1 associated proteins using the yeast two-hybrid system, led to the identification of thioredoxin (Saitoh et al., 1998). Thioredoxin association with ASK1 was found in non-stressed cells and required the amino-terminal domain of ASK1. Thioredoxin association with ASK1 inhibits its activity as a kinase. Deletion of specific amino-terminal residues renders ASK1 constitutively active, and no longer influenced by thioredoxin. Thioredoxin inhibition of ASK1 is subject to attenuation by ROS, which induce dimerization of thioredoxin. ROS-dependent dissociation of thioredoxin from ASK1 is abolished upon treatment of cells with free radical scavengers. Further support for the role of thioredoxin in inhibition of ASK1 comes from the use of antisense to thioredoxin, which has also been shown to attenuate ASK1 inhibition. Of interest is the finding that ASK1 can undergo multimerization in response to ROS and thus has been associated with the active form of the kinase (Gotoh and Cooper, 1998). This suggests that thioredoxin association with ASK1 may serve to prevent its multimerization. The finding that signaling to apoptosis via DAXX is also mediated via the amino-terminal domain of ASK1 (Chang et al., 1998), suggests that dissociation of thioredoxin from ASK1 may also be accomplished upon the association of ASK1 with other cellular proteins. Alternatively, since ROS is normally expected to accumulate in response to either TNF or Fas signaling, ASK1 activation could occur via displacement of the inhibitory protein thioredoxin with an activating one, such as DAXX.
Thioredoxin-glucocorticoid receptor
Glucocorticoid receptors (GR) belong to a group of transcription factors that are redox responsive. A mammalian two hybrid assay revealed direct association between thioredoxin and GR. Such an association is mediated via the DNA binding domain, which is highly conserved among other nuclear receptors, thus suggesting that similar association and regulation may also exist for other members of this receptor family. Interaction between thioredoxin and GR was found to take place in the nuclei under oxidative conditions (Makino et al., 1999).
GSTp-JNK
ASK1 has been implicated in the activation of MKK3/6, MKK4/MKK7 and subsequently, p38 or JNK (Ichijo et al., 1997), resulting in the phosphorylation of respective p38 and JNK substrates, including ATF2, c-Jun, (reviewed by Ip and Davis, 1998) and p53 (Adler et al., 1997; Fuchs et al., 1998a). The key role of these substrates in the cellular protection from stress and damage suggests that their kinases should be tightly regulated. One indicator for such regulation is the low basal activity of JNK in cells, even if maintained under high concentration of growth factors, which were shown to serve as potent inducers of JNK (Minden et al., 1994). This suggests that JNK activity is inhibited in non-stressed cells. Indeed, extracts prepared from normal growing cells contain an inhibitory component which was purified and identified through microsequencing as GSTp (Adler et al., 1999). GSTp inhibition of JNK activity requires its association, which, in turn, limits the degree of Jun phosphorylation under non stressed growth conditions. GSTp-JNK association was primarily found in non-stressed cells. Upon treatment with H2O2 or UV, GSTp dissociated from JNK and formed dimers/multimers. Under physiological conditions GSTp inhibition was limited to JNK and did not involve the upstream JNK kinase MKK4. Furthermore, in the cells over-expressing GSTp, constitutively active MEKK1 efficiently phosphorylated both MKK4 and JNK, but did not elicit Jun phosphorylation due to GSTp-mediated inhibition. These observations suggest that GSTp-mediated inhibition of JNK is maintained upon the association between JNK and GSTp, regardless of the activation of JNK per se. Free radical scavengers maintain the GST-JNK association and JNK inhibition by GSTp. GSTp inhibitors as well as a GSTp-derived peptides were able to alter the degree of JNK activity prior to and after UV-irradiation, further defining the nature of this inhibition. Cells derived from GSTp null cells were found to have high basal JNK activity, which was reduced upon forced expression of GSTp cDNA (Adler et al., 1999). Being a key regulator of glutathione and, in turn, of redox potential, the identification of GSTp as a JNK regulator provides an important link between cellular redox potential and the regulation of stress kinase activities.
PAG-cAbl
PAG, a 23 kDa protein, was found to interact with c-Abl through the SH3 domain of c-Abl. This association mediated the inhibition of c-Abl tyrosine kinase activity and rescued cytostatic and cytotoxic effects mediated by c-Abl. Dissociation of Pag and c-Abl is thought to be caused by the elevation of ROS level in cells (Wen and Van Etten, 1997).
Direct effects of ROS on protein kinases
ROS-induced dimerization of ASK1
TNFα or H2O2 treatments caused ASK1-dependent apoptosis and concomitantly revealed changes from monomeric to dimeric or higher order oligomeric forms of ASK1. Pretreatment with free radical scavengers decreased these dimeric/multimeric forms and reduced ASK1 activity and the extent of apoptosis. Synthetic dimerization of an ASK1-gyrase B fusion protein by coumermycin resulted in substantial activation of ASK1, suggesting that dimerization of ASK1 is sufficient for its activation (Gotoh and Cooper, 1998). Respectively, it is possible that ROS activates ASK1 via induction of ASK1 oligomerization.
Redox effects on p21ras, Rac1 and PI3K
p21ras has been shown to serve as a redox responsive signaling molecule (Lander et al., 1995, 19961996). Moreover, cells expressing the mutant ras (H-ras-V12) were shown to produce a large amount of ROS (Irani et al., 1997), resulting in the activation of MAPK, ERK, ELK1 and c-fos (Muller et al., 1997a,b). Molecular interactions between nitric oxide (NO) and p21ras activates p21-mediated signaling. Such an interaction results in S-nitrosylation of p21ras on cysteine 118. Mutant forms of p21ras at cysteine 118 no longer mediate guanine nucleotide exchange and further downstream signaling (i.e. activation of MAPK cascade) by NO (Lander et al., 1997). ROS were also reported to mediate recruitment of PI3K to p21ras, an association that contributed to activation of PKB/Akt and MAPK, which are downstream targets for these kinases, respectively (Deora et al., 1998). Of interest is the independent role implicated for p85, the regulatory subunit of PI3K, in p53-dependent apoptotic response to oxidative stress (Yin et al., 1998).
Another GTP binding protein, Rac1, has been associated with the generation of ROS and activation of NF-κB (Sundaresan et al., 1996; Sulciner et al., 1996). ROS activation of Rac1 has also been implicated in the alteration of cell shape via transactivation of interleukin1α and of collagenase-1, both of which affect cellular cytoskeleton reorganization associated with wound healing, inflammation and malignancy (Kheradmand et al., 1998).
Redox modification of PKC
As a phorbol ester and oxidant responsive kinase, PKC has unique redox active cysteine-rich regions. Selenocompounds have been shown to affect PKC activity, in a concentration-dependent manner. Such alterations are mediated via the formation of disulfide bridges contingent upon the dose administered. At low dose, two disulfide bridges were identified between four cysteines, whereas at high concentrations, up to four disulfide bridges were formed (Gopalakrishna et al., 1997). These observations suggest that the cysteine residues present within the catalytic domain of the different PKC isoenzymes, although apart in the sequence, may be clustered in the tertiary structure to react with selenite, as well as being in a close proximity to some of the cysteines in the regulatory domain.
Redox modifications of substrates
Neurogranin
Neurogranin (Ng) is a neuron specific protein kinase C selective substrate that binds calmodulin (CaM) in the dephosphorylated form (Sheu et al., 1996). Ng contains active cysteine residues that are readily oxidized by several nitric oxide donors as well as by other oxidants to form intracellular disulfides. The cysteine residues involved in NO-mediated intramolecular disulfide bridge formation are at positions 3, 4, 9 and 51. While mutation at cysteine 51 abrogated disulfide bridge formation, it was necessary to mutate the other three sites (3, 4 and 9) to achieve the same effect. The intramolecular disulfide bridge between Ng proteins displayed dramatically attenuated CaM binding affinity and 2 – 3-fold weaker phosphorylation by PKC (Mahoney et al., 1996).
Rieske iron-sulphur protein – example of redox effect on RNA synthesis
The observation that ROS mediated redox changes decreased RNA synthesis in potato mitochondria led to identification of the Rieske iron sulphur protein as a key determinant in reducing the rate of UTP incorporation upon oxidative burst. Furthermore, broad-spectrum protein phosphatase inhibitors also decreased (up to 50%) UTP incorporation (Wilson et al., 1996). The latter observation implies that redox effects on RNA synthesis may be mediated in part via protein phosphorylation.
Redox effect on mRNA stability
Changes in the stability of mRNA of p21waf1/cip1 and interleukin's 2 and 3 were recorded upon treatment with ROS producing agents, or via activation of ROS responsive kinases. The elevated expression of p21waf1/cip1 in response to a variety of DNA damaging and ROS generating agents was also shown to be p53-independent. Increased levels of mRNA were found to be due to the ROS-dependent increased stability since exposure to free radical scavengers attenuated this increase (Esposito et al., 1997). Of interest is a possible link between elevated ROS-mediated p21WAF1/cip1 expression and a reported role of ROS in senescence (Chen et al., 1995).
Activation of JNK by various forms of stress forming ROS results in the stabilization of mRNA for interleukins 2 and 3. This phenomenon is mediated through specific elements in the 5′ and 3′ UTRs for IL2 and 3′ UTR for IL3 (Chen et al., 1998; Ming et al., 1998). While the nature of JNK role in this stabilization is to be determined, the JNK-dependency points to a clear relationship between ROS and the stabilization of these mRNAs. Furthermore, altered cellular redox has been shown to prolong the half-lives of both the transcript and protein for GSTP1-1 (Shen et al., 1995). This observation could have implications to the overall model of redox reactive thiol control proposed in this review.
Redox effect on protein stability
Iron has been shown to be an important cellular cofactor involved in the maintenance of balanced ROS level. IRP2, a protein that is responsible for iron uptake and distribution is degraded by the proteasome in iron-replete cells. Iron dependent oxidation converts IRP2 into a substrate for ubiquitination in vitro. Thus, excess iron is `sensed' by its ability to catalyze site specific oxidations in IRP2. Oxidized IRP2 is efficiently ubiquitinated and degraded (Iwai et al., 1998). A link between ROS and protein stability was also demonstrated via GST inhibitory effects on JNK, which targets its non-phosphorylated substrates for ubiquitination and degradation (Fuchs et al., 1998b). In this setting, GST inhibition of JNK results in a lower level of c-Jun phosphorylation and respective increase in Jun ubiquitination (Adler et al., 1999).
Thioredoxin effects on transcription factors
Earlier studies have demonstrated the effects of thioredoxin on stress activated transcription factors, primarily from the AP1 and NF-κB families, (reviewed in Schulze-Osthoff et al., 1995; Sen and Packer, 1996; Okamoto et al., 1997; Flohe et al., 1997 and Mercurio and Manning, this issue). In this respect the opposing effects of thioredoxin on AP1 and NF-κB are interesting. While inhibiting the transcriptional activities of NF-κB, thioredoxin was shown to activate AP1-mediated transcription (Meyer et al., 1993; Schenk et al., 1994). The latter may provide an explanation for scenarios where activation of NF-κB (upon hyperoxia) provides protection from apoptosis (Li et al., 1997).
Among the possible mechanisms that could underlie the effect of thioredoxin on these transcription factors are (i) changes to upstream kinases, as demonstrated for ASK1 (ii), its direct effects on the transcription factor as shown for GR and (iii) its effect on a mediator protein, as shown for Ref1. Ref1 is a dual functional protein that plays an important role in the repair of a-basic sites via its apurinic/apyrimidinic endonuclease activity, and also elicits a redox-responsive regulation of c-Jun /NF-κB transcription. While phosphorylation by CKII has been thought to play a regulatory role in its DNA repair activity (Yacoub et al., 1997), altered ROS determines the association and nature of the Ref1 effect on the transcription factor's activity. Thioredoxin activation of AP1 is explained by its association with Ref1, which binds to AP1 and renders it transcriptionally active. Mutations on specific cysteines on thioredoxin abolished its association with Ref1 and consequently reduced Ref1's ability to mediate AP1 transactivation. Respective cysteines on c-Jun and c-fos were also mapped (Nikitovic et al., 1998).
Similar to thioredoxin's effect on AP1, a relationship between thioredoxin and the transcriptional activity of p53 was demonstrated in Saccharomyces cerevisiae, as deletion of the thioredoxin gene led to inhibition of p53-mediated transcription (Pearson and Merril, 1998). The effect of thioredoxin on p53 may occur in a fashion similar to the thioredoxin effects on AP1, i.e. via Ref1. This is proposed based on the established role of Ref1 in regulation of p53 transcriptional activities depending on the redox status and oxidized state of p53 (Jayaraman et al., 1997). Thus, a Ref1-thioredoxin complex may also participate in the regulation of p53 by ROS. The role of ROS in p53-mediated apoptosis has been demonstrated (Johnson et al., 1996). Furthermore, an increased tumor cells capacity for undergoing apoptosis in response to ROS was also shown to be p53-dependent (Graeber et al., 1996). This is consistent with the increased radio sensitivity that has been associated with oxidative signaling in repair deficient syndromes, such as ataxia telangiectasia (Lavin, 1998).
Runt domain proteins are transcriptional regulators that specify cells' fate for processes extending from pattern formation in insects to leukemogenesis in humans. The transcription factor PEBP2/CBF consists of a DNA binding subunit which has an evolutionary conserved 128-amino acid region termed `Runt domain', responsible for DNA binding and heterodimerization with beta subunit. The Runt domain contains two conserved cysteins (aa 115, 124) which are responsible for redox regulation. Furthermore, two thiol-reactive proteins, thioredoxin and Ref1 play a role in the positive activation of the Runt domain (Akamatsu et al., 1997). Runt domain is dynamically regulated by altered potential.
Viral infection and ROS
Several studies have pointed to the ability of DNA and RNA viruses including influenza, paramyxovirus, hepatitis B virus and HIV to lead to the formation of ROS (reviewed in Schwarz, 1996). In most cases, this has been a consequence of the activation of monocytes and polymorphonuclear leukocytes. The relationship between viral infection and ROS production is better elucidated for HIV. HIV-induced apoptosis is thought to underlie the efficient depletion of T cells. T cell apoptosis by HIV is preceded by an exponential increase in reactive oxygen intermediates produced in the mitochondria, leading to caspase 3 activation, phosphatidylserine externalization and GSH depletion. Trans-aldolase is a key enzyme in the pentose phosphate pathway, which govern the supply of NADPH to mitochondria, the latter being a major determinant of ROS levels (Banki et al., 1998).
Overexpression of trans-aldolase increased ROS formation and apoptosis induced by HIV, whereas down regulation of trans-aldolase via the use of antisense expressing trans-aldolase constructs had the opposite effect (Banki et al., 1998). Thus, manipulation of GSH production and ROS generation in the mitochondria of HIV infected cells may control the degree of apoptosis induced by this virus. Another example of a viral protein, which has been associated with generation of ROS, is bovine papilloma virus E5 that was shown to induce NF-κB via superoxide radicals (Kilk et al., 1996).
The feedback loop of redox responsive proteins
While normal growing cells frequently express the monomeric form of cysteine rich redox sensitive molecules, such as thioredoxin and GSTp, exposure to ROS generating stress results in their dimerization and inactivates their normal maintenance functions. While the fate of the multimer forms of thioredoxin and GSTp has yet to be investigated, it is assumed that they will be subjected to accelerated degradation. At the same time, stress treatments mediate new synthesis of these redox responsive proteins. For example, heat shock was shown to increase transcriptional activation of thioredoxin (Leppa et al., 1997), thereby providing a new pool of monomeric thioredoxin that is expected to re-establish inhibition of ASK1 and its effectors. Similarly, GST and related family members are frequently identified as p53 inducible proteins (Polyak et al., 1997; Komarova et al., 1998). Another JNK substrate, c-Jun was also shown to increase GSTp expression (Ainbinder et al., 1997). Therefore, similar to the case of thioredoxin, synthesis of new monomeric forms of GST may take place hours after altered redox potential, which could then assure new production of monomeric GST in the recovering cells resuming inhibition of JNK activity. In addition to its effects on JNK, GST was found to play an important role in coordinated regulation of ERK, p38 and NF-κB (Yin et al., unpublished observations). Of interest is the finding that protein synthesis is also required for the production of ROS and glutathione depletion, as shown in cellular response to TGFβ in fetal rat hepatocytes (Sanchez et al., 1997). This suggests that other cellular components, possibly other redox regulating enzymes, may also determine cellular fate through altering levels of oxygen radicals, thereby representing an escalating cellular loop that is expected to lead to an enhanced rate of apoptosis.
Discussion
Examples given in this review clearly suggest that ROS effects on cellular stress response involve almost all cellular compartments and regulatory levels (Figure 1). From its direct or cis-effects on redox responsive proteins which regulate key stress kinases and transcription factors, to the direct effect on signaling components such as p21ras, and further to transcription factors at the level of RNA translation, RNA and protein stability. Our current knowledge points to the existence of ROS-related feedback loops, which ensure that the changes elicited upon ROS formation will be homeostatic and cyclical. Given the complexity of ROS regulating enzyme/systems, one could envision additional regulatory circuits that could increase the degree of sensitivity and responsiveness. For example, glutathione depletion has been implicated in the regulation of stress kinases JNK and p38 (Wilhelm et al., 1997), inactivation of PKC (Ward et al., 1998) and attenuated Bcl2 inhibition of apoptotic protease (AP24) which induces DNA fragmentation (Wright et al., 1998), although the nature of these changes is not completely understood. The current state of knowledge also permits the design of peptides and pharmacomimetic reagents that selectively block stress responsive pathways, as a possible means to alter cellular responses to ROS. Since tumor cells are often found to express elevated levels of ROS responsive proteins and consequently, different drug resistance and apoptotic capacity, it is suggested that altering ROS control may sensitize tumor cells for a better response to selective treatments.
Changes elicited to stress responsive kinases and transcription factors following production of ROS are shown. Arrows point to either dissociation or association of corresponding molecules in response to the generation of ROS, represented here by H2O2. Shown is PAG dissociation from c-Abl which maintains inhibition of c-Abl under non stressed conditions. Dimerization of thioredoxin (trx) results in its dissociation from ASK1, enabling ASK1 dimerization and activation. Similarly, dimerization of GSTp relieves JNK from GSTp-mediated inhibition thus allowing JNK phosphorylation of its substrates, Jun, ATF2 and p53. ROS recruits PI3K to p21ras, leading to the activation of the MAPK and PKB pathways. While the dimerized form of thioredoxin dissociates from respective kinases, within the nuclei it has been shown to associate with the glucocorticoid receptor (GR), which increases GR transcriptional activities. Effect of ROS on mRNA stabilization of p21waf and interleukins is also indicated in the figure
Abbreviations
- ASK:
-
apoptosis signal-regulating kinase
- ERK:
-
extracellular signal regulated kinase
- GR:
-
glucocorticoid receptor NO -nitric oxide
- GST:
-
glutathione S-transferase
- IRP:
-
iron responsive protein
- JNK:
-
Jun NH2 terminal kinase
- MAPK:
-
mitogen activated protein kinase
- Ng:
-
neurogranin
- PI3K:
-
phosphoinositol 3 kinase
- PKC:
-
protein kinase C
- ROS:
-
reactive oxygen species
- TNF:
-
tumor necrosis factor
References
Abe J, Kusuhara M, Ulevitch RJ, Berk BC and Lee JD. . 1996 J. Biol. Chem. 271: 16586–16590.
Abe J, Takahashi M, Ishida M, Lee JD and Berk B. . 1997 J. Biol. Chem. 272: 20389–20394.
Adler V, Pincus MR, Minamoto T, Fuchs SY, Bluth MJ, Brandt-Rauf PW, Friedman FK, Robinson RC, Chen JM, Wang XW, Harris CC and Ronai Z. . 1997 Proc. Natl. Acad. Sci. USA 94: 1686–1691.
Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, Davis R and Ronai Z. . 1999 EMBO J. 18: 1321–1334.
Ainbinder E, Bergelson S, Pinkus R and Daniel V. . 1997 Eur. J. Biochem. 243: 49–57.
Akamatsu Y, Ohno T, Hirota K, Kagoshima H, Yodoi J and Shigesada K. . 1997 J. Biol. Chem. 272: 14497–14500.
Banki K, Hutter E, Gonchoroff NJ and Perl A. . 1998 J. Biol. Chem. 273: 11944–11953.
Biguet C, Wakasugi N, Mishal Z, Holmgren A, Chouaib S, Tursz T and Wakasugi H. . 1994 J. Biol. Chem. 269: 28865–28870.
Cavigelli M, Li WW, Lin A, Su B, Yoshioka K and Karin M. . 1996 EMBO J. 20: 6269–6279.
Chakraborti S and Chakraborti T. . 1998 Cell Signal 10: 675–683.
Chang HY, Nishitoh H, Yang X, Ichijo H and Baltimore D. . 1998 Science 281: 1860–1863.
Chen CY, Del Gatto-Konczak F, Wu Z and Karin M. . 1998 Science 280: 1945–1949.
Chen Q, Fischer A, Reagan JD, Yan L-J and Ames BN. . 1995 Proc. Natl. Acad. Sci. USA 92: 4337–4341.
Cooper JA and Gotoh Y. . 1998 J. Biol. Chem. 273: 17477–17482.
Deora AA, Win T, Vanhaesebroeck B and Lander HM. . 1998 J. Biol. Chem. 273: 29923–29928.
Dimon-Gadal S, Gerbaud P, Keryer G, Anderson W, Evain-Brion D and Raynaud F. . 1998 J. Biol. Chem. 273: 22833–22840.
Duhe RJ, Evans GA, Erwin RA, Kirken RA, Cox GW and Farrar WL. . 1998 Proc. Natl. Acad. Sci. USA 95: 126–131.
Ellerby LM, Ellerby HM, Park SM, Holleran AL, Murphy AN, Fiskum G, Kane DJ, Testa MP, Kayalar C and Bredesen DE. . 1996 J. Neurochem. 67: 1259–1267.
Esposito F, Cuccovillo F, Vanoni M, Cimino F, Anderson CW, Apella E and Russo T. . 1997 Eur. J. Biochem. 245: 730–737.
Flohe L, Brigelius-Flohe R, Saliou C, Traber MG and Packer L. . 1997 Free Radic. Biol. Med. 22: 1115–1126.
Fuchs SY, Adler V, Pincus MR and Ronai Z. . 1998a Proc. Natl. Acad. Sci. USA 95: 10541–10546.
Fuchs SY, Fried VA and Ronai Z. . 1988b Oncogene 17: 1483–1490.
Goldstone SD and Hunt NH. . 1997 Biochim. Biophys. Acta 1355: 353–360.
Gomez del Arco P, Martinez-Martinez S, Calvo V, Armesilla AL and Redondo JM. . 1996 J. Biol. Chem. 271: 26335–26240.
Gopalakrishna R, Gundimeda U and Chen ZH. . 1997 Arch. Biochem. Biophys. 348: 25–36.
Gotoh Y and Cooper JA. . 1998 J. Biol. Chem. 273: 17477–17482.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ. . 1996 Nature 379: 88–91.
Hamm-Kunzelmann B, Schafer D, Weigert C and Brand K. . 1997 FEBS Lett. 403: 87–90.
Hayashi H, Iimuro M, Matsumoto Y and Kaneko M. . 1998 Eur. J. Pharmacol. 349: 133–136.
Hayes JD and Pulford DJ. . 1995 Crit. Rev. Biochem. Mol. Biol. 30: 445–600.
Ip YT and Davis RJ. . 1998 Curr. Opin. Cell Biol. 10: 205–219.
Ichijo H, Nishida E, Irie K, Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyzaono K and Gotoh Y. . 1997 Science 275: 90–94.
Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearson ER, Sundaresan M, Finkel T and Goldschmidt-Clermont PJ. . 1997 Science 275: 1649–1652.
Iwai K, Drake SK, Wehr NB, Weissman AM, La Vaute T, Minato N, Klausner RD, Levine RL and Rouault TA. . 1998 Proc. Natl. Acad. Sci. USA 95: 4924–4928.
Jayaraman L, Murthy KGK, Zhu C, Curran T, Xanthoudakis S and Prives C. . 1997 Genes Dev. 11: 558–570.
Johnson TM, Yu Z-X, Ferrans VJ, Lowenstein RA and Finkel T. . 1996 Proc. Natl Acad. Sci. USA 93: 11848–11852.
Kang CD, Jang JH, Kim KW, Lee HJ, Jeong CS, Kim CM, Kim SH and Chung BS. . 1998 Neurosci. Lett. 256: 37–40.
Kanterewicz BI, Knapp LT and Klann E. . 1998 J. Neurochem. 70: 1009–1016.
Kilk A, Talpsepp T, Vali U and Ustav M. . 1996 Biochem. Mol. Biol. Int. 40: 689–697.
Kheradmand F, Werner E, Tremble P, Symons M and Werb Z. . 1998 Science 280: 898–902.
Komarova EA, Diatchenko L, Rokhlin OW, Hill JE, Wang ZJ, Krivokrysenko VI, Feinstein E and Gudkov AV. . 1998 Oncogene 17: 1089–1096.
Krejsa CM, Nadler SG, Esselstyn JM, Kavanagh TJ, Ledbetter JA and Schieven GL. . 1997 J. Biol. Chem. 272: 11541–11549.
Kuo ML, Lee KC, Lin JK, Huang TS. . 1995 Biochim. Biophys. Acta 1268: 229–236.
Laderoute KR and Webster KA. . 1997 Circ. Res. 80: 336–344.
Lander HM, Haijar DP, Hempstead BL, Mirza UA, Chait BT, Campbell S and Quilliam LA. . 1997 J. Biol. Chem. 272: 4323–4326.
Lander HM, Jacovina AT, Davis RJ and Tauras JM. . 1996 J. Biol. Chem. 272: 19705–19709.
Lander HM, Milbank AJ, Tauras JM, Hajjar DP, Hempstead BL, Schwartz GD, Kraemer RT, Mirza UA, Chait BT, Burk SC and Quilliam LA. . 1996 Nature 381: 380–381.
Lander HM, Ogiste JS, Teng KK and Novogrodsky A. . 1995 J. Biol. Chem. 270: 21195–21198.
Lavin MF. . 1998 Radiother. Oncol. 47: 113–123.
Leclerc P, de Lamirande E and Gagnon C. . 1997 Free Radic. Biol. Med. 22: 643–656.
Leppa S, Prikkala L, Chow SC, Eriksson JE and Sistonen L. . 1997 J. Biol. Chem. 272: 30400–30404.
Li D, Yang B and Mehta JL. . 1998 Am. J. Physiol. 275: H568–H576.
Li Y, Zhang W, Mantell LL, Kazzaz JA, Fein AM and Horowitz S. . 1997 J. Biol. Chem. 272: 20646–20649.
Lim Y, Kim SH, Kim KA, Oh MW and Lee KH. . 1997 Environ. Health Perspect. 105: 1325–1327.
Liu GY, Frank N, Bartsch H and Lin JK. . 1998 Mol. Carcinogen. 22: 235–246.
Ludwig S, Hoffmeyer A, Goebeler M, Killian K, Haffner H, Neufeld B, Han J and Rapp UR. . 1998 J. Biol. Chem. 273: 1917–1922.
Luo Y, Umegaki H, Wang X, Abe R and Roth GS. . 1998 J. Biol. Chem. 273: 3756–3764.
Mahoney CW, Pak JH and Huang KP. . 1996 J. Biol. Chem. 271: 28798–28804.
Makino Y, Yoshikawa N, Okamoto K, Hirota K, Yodoi J, Makino I and Tanaka H. . 1999 J. Biol. Chem. 274: 3182–3188.
McConkey DJ and Orrenius S. . 1996 Stem. Cells 14: 619–631.
Meyer M, Schreck R and Baeuerle PA. . 1993 EMBO J. 12: 2005–2015.
Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL and Karin M. . 1994 Science 266: 1719–1723.
Ming XF, Kaiser M and Moroni C. . 1998 EMBO J. 17: 6039–6048.
Monteiro HP and Stern A. . 1996 Free Radic. Biol. Med. 21: 323–333.
Muller JM, Cahill MA, Rupec RA, Baeuerle PA and Nordheim A. . 1997a Eur. J. Biochem. 244: 45–52.
Muller JM, Krauss B, Kaltschmidt C, Baeuerle PA and Rupec RA. . 1997b J. Biol. Chem. 272: 23435–23439.
Nakano H, Kimura J, Kumano T, Hanada K, Satoh K, Hashimoto I and Tsuchida S. . 1997 Jpn. J. Cancer Res. 88: 1063–1069.
Nikitovic D, Holmgren A and Spyrou G. . 1998 Biochem. Biophys. Res. Commun. 242: 109–112.
Okamoto T, Sakurada S, Yang JP and Merin JP. . 1997 Curr. Top Cell Regul. 35: 149–161.
Pearson GD and Merril GF. . 1998 J. Biol. Chem. 273: 5431–5434.
Piette J, Piret B, Bonizzi G, Schoonbroodt S, Merville MP, Legrand-Poels S and Bours B. . 1997 Biol. Chem. 378: 1237–1245.
Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B. . 1997 Nature 389: 300–305.
Powis G, Briehl M and Oblong J. . 1995 Pharmacol. Ther. 68: 149–173.
Primiano T, Sutter TR and Kensler TW. . 1997 Comp. Biochem. Physiol. Biochem. Mol. Biol. 118: 487–497.
Pu M, Akhand AA, Kato M, Hamaguchi M, Koike T, Iwata H, Sabe H, Suzuki H and Nakashima I. . 1996 Oncogene 13: 2615–2622.
Qiu X, Forman HJ, Schonthal AH and Cadenas E. . 1996 J. Biol. Chem. 271: 31915–31921.
Russel M. . 1995 Methods Enzymol. 252: 264–274.
Sabri A, Byron KL, Samarel AM, Bell J and Lucchesi PA. . 1998 Circ. Res. 82: 1053–1062.
Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K and Ichijo H. . 1998 EMBO J. 17: 2596–2606.
Sanchez A, Alvarez AM, Benito M and Fabregat I. . 1997 Hepatology 26: 935–943.
Schenk H, Klein M, Erdbrugger W, Droge W and Schulze-Osthoff K. . 1994 Proc. Natl. Acad. Sci. USA 91: 1672–1676.
Schulze-Osthoff K, Schenk H and Droge W. . 1995 Methods Enzymol. 252: 264.
Schwarz KB. . 1996 Free Radic. Biol. Med. 21: 641–649.
Scotto C, Mely Y, Ohshima H, Garin J, Cochet C, Chambaz E and Baudier J. . 1998 J. Biol. Chem. 273: 3901–3908.
Sen CK and Packer L. . 1996 FASEB J. 10: 709–720.
Shen H, Rangamathan S, Kumich S and Tew KD. . 1995 Biochem. Pharmacol. 50: 1233–1238.
Sheu F-W, Mahoney CW, Seki K and Huang K-P. . 1996 J. Biol. Chem. 271: 22407–22413.
Simon G, Moog C and Obert G. . 1994 Chem. Biol. Interact. 91: 217–224.
Sulciner DJ, Irani K, Yu ZX, Ferrans VJ, Goldschmidt-Clermont P and Finkel T. . 1996 Mol. Cell Biol. 16: 711521.
Sundaresan M, Yu ZX, Ferans VJ, Sulciner DJ, Gutkind JS, Irani K and Goldschmidt-Clermont PJ. . 1996 Biochem. J. 318: 379–382.
Taher MM, Mahgoub MA and Abd-Elfattah AS. . 1998 J. Recept Signal Transduct Res. 18: 167–185.
Tan CM, Xenoyannis S, Feldman RD. . 1995 Circ. Res. 77: 710–717.
Tan S, Wood M and Maher P. . 1998 J. Neurochem. 71: 95–105.
Tew, KD. . 1994 Cancer Res. 54: 4313–4320.
Torti SV, Akimoto H, Lin K, Billingham ME and Torti FM. . 1998 J. Mol. Cell Cardiol. 30: 1173–1180.
Ushio-Fukai M, Alexander RW, Akers M and Griendling KK. . 1998 J. Biol. Chem. 273: 15022–15029.
Wang D, Yu X and Brecher P. . 1998a J. Biol. Chem. 273: 33027–33034.
Wang X, Martindale JL, Liu Y and Holbrook NJ. . 1998b Biochem. J. 333: 291–300.
Ward NE, Pierce DS, Chung SE, Gravitt KR and O'Brian CA. . 1998 J. Biol. Chem. 273: 12558–12566.
Warner BB, Stuart L, Gebb S and Wispe JR. . 1996 Am. J. Physiol. 271: 150–158.
Wen ST and Van Etten RA. . 1997 Genes Dev. 11: 2456–2467.
Wilhelm D, Bender K, Knebel A and Angel P. . 1997 Mol. Cell Biol. 17: 4792–4800.
Wilson SB, Davidson GS, Thomson LM and Pearson CK. . 1996 Eur. J. Biochem. 242: 81–85.
Wright SC, Wang H, Wei QS, Kinder DH and Larrick JW. . 1998 Cancer Res. 58: 5570–5576.
Yacoub A, Kelly MR and Deutsch WA. . 1997 Cancer Res. 57: 5457–5459.
Yin Y, Terauchi Y, Solomon GG, Aizawa S, Rangarajan PN, Yazaki Y, Kadowaki T and Barrett JC. . 1998 Nature 391: 707–710.
Acknowledgements
We thank Serge Fuchs for helpful comments. Support by NIH grant CA77389 (to Z Ronai) is gratefully acknowledged.
Author information
Affiliations
Rights and permissions
About this article
Cite this article
Adler, V., Yin, Z., Tew, K. et al. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 18, 6104–6111 (1999). https://doi.org/10.1038/sj.onc.1203128
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203128
Keywords
- stress kinases
- oxygen radicals
- ROS
- GST
- thioredoxin
- NF-κB
Further reading
-
Anti-hypertensive effect of hydrogen peroxide acting centrally
Hypertension Research (2020)
-
Multi-scale impact of chronic exposure to environmental concentrations of chlordecone in freshwater cnidarian, Hydra circumcincta
Environmental Science and Pollution Research (2020)
-
Pharmacogenetic Markers for Metabolic Impairments in Treatment with Valproic Acid
Neuroscience and Behavioral Physiology (2020)
-
Comparative transcriptomics suggest unique molecular adaptations within tardigrade lineages
BMC Genomics (2019)
-
Activation of antioxidant defences of human mammary epithelial cells under leptin depend on neoplastic state
BMC Cancer (2018)
